Clinical and molecular rationale to retain the cancer descriptor for Gleason score 6 disease.

about

Clinical and molecular rationale to retain the cancer descriptor for Gleason score 6 disease.

Item

http://www.wikidata.org/entity/Q39023426

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Clinical and molecular rationa ...... r for Gleason score 6 disease.

@en

Clinical and molecular rationa ...... r for Gleason score 6 disease.

@nl

type

Item

label

Clinical and molecular rationa ...... r for Gleason score 6 disease.

@en

Clinical and molecular rationa ...... r for Gleason score 6 disease.

@nl

prefLabel

Clinical and molecular rationa ...... r for Gleason score 6 disease.

@en

Clinical and molecular rationa ...... r for Gleason score 6 disease.

@nl

P1476

Clinical and molecular rationa ...... r for Gleason score 6 disease.

@en

P2093

Chad A Reichard

http://www.w3.org/2001/XMLSchema#string

Eric A Klein

http://www.w3.org/2001/XMLSchema#string

P2860

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer

Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy

Predicting 15-year prostate cancer specific mortality after radical prostatectomy.

Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.

Radical prostatectomy or watchful waiting in early prostate cancer.

Ongoing Gleason grade migration in localized prostate cancer and implications for use of active surveillance.

Prognostic Gleason grade grouping: data based on the modified Gleason scoring system.

Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.

The evolutionary history of lethal metastatic prostate cancer.

Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.

P2888

nrurol.2016.240

P304

59-64

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRUROL.2016.240

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27898099

http://www.w3.org/2001/XMLSchema#string